Patents by Inventor Ya-Wei Tsai

Ya-Wei Tsai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-GRP78 ANTIBODIES AND THEIR USES
    Publication number: 20250019426
    Abstract: The present disclosure relates to an anti-glucose-regulated protein 78 (GRP78) antibody or an antigen-binding fragment thereof. The present disclosure also relates to a method for treating and/or preventing a disease and/or disorder caused by or related to GRP78 activity or signaling, and a method or kit for detecting GRP78 or a cancer in a sample.
    Type: Application
    Filed: July 3, 2024
    Publication date: January 16, 2025
    Applicant: UCT BIOSCIENCE CO., LTD.
    Inventors: CHIA-CHENG WU, YA-WEI TSAI, TZU-YIN LIN, CHIA-HSIANG LO
  • Antibodies specific to alpha-enolase and uses thereof
    Patent number: 10781266
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 22, 2020
    Assignees: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Po-Yin Lin, Ya-Wei Tsai, Chao-Yang Huang, Ying-Yung Lok, Chung-Hsiun Wu, Hsien-Yu Tsai, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
  • ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND USES THEREOF
    Publication number: 20190322762
    Abstract: An antibody, or an antigen-binding fragment there, binding human ENO1 (GenBank: AAH506421.1) is provided. Methods for treating an ENO1 protein-related disease or disorder, inhibiting cancer invasion and diagnosis of cancer are also provided.
    Type: Application
    Filed: March 19, 2018
    Publication date: October 24, 2019
    Applicants: DEVELOPMENT CENTER FOR BIOTECHNOLOGY, NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: SHIH-CHONG TSAI, TA-TUNG YUAN, SHIH-CHI TSENG, JIANN-SHIUN LAI, CHIA-CHENG WU, PO-YIN LIN, YA-WEI TSAI, CHAO-YANG HUANG, YING-YUNG LOK, CHUNG-HSIUN WU, HSIEN-YU TSAI, NENG-YAO SHIH, KO-JIUNN LIU, LI-TZONG CHEN
  • Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy
    Patent number: 9527922
    Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: December 27, 2016
    Assignees: Development Center for Biotechnology, DCB-USA LLC, National Health Research Institutes
    Inventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen
  • HUMANIZED ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY
    Publication number: 20160185876
    Abstract: A humanized antibody, or a binding fragment thereof, wherein the humanized antibody binds human ENO1 (GenBank: AAH50642.1), wherein the antibody comprises a light chain variable region (VL) domain comprising a CDR1 having the amino acid sequence LCDR1 (RASENIYSYLT; SEQ ID NO: 6) and a CDR2 having the amino acid sequence LCDR2 (NAKTLPE; SEQ ID NO: 7) and a CDR3 having the amino acid sequence LCDR3 (QHHYGTPYT; SEQ ID NO: 8) and an antibody heavy chain variable region (VH) domain comprising a CDR1 having the amino acid sequence HCDR1 (GYTFTSCVMN; SEQ ID NO: 3), a CDR2 having the amino acid sequence HCDR2 (YINPYNDGTKYNEKFKG; SEQ ID NO: 4) and a CDR3 having the amino acid sequence HCDR3 (EGFYYGNFDN; SEQ ID NO: 5), wherein framework regions in the light chain variable region (VL) domain and the heavy chain variable region (VH) domain comprise amino acid sequences from a human immunoglobulin.
    Type: Application
    Filed: December 31, 2014
    Publication date: June 30, 2016
    Applicants: Development Center for Biotechnology, DCB-USA LLC, National Health Research Institutes
    Inventors: Shih-Chong Tsai, Ta-Tung Yuan, Shih-Chi Tseng, Jiann-Shiun Lai, Chia-Cheng Wu, Chao-Yang Huang, Ya-Wei Tsai, Ying-Yung Lok, Chung-Hsiun Wu, Neng-Yao Shih, Ko-Jiunn Liu, Li-Tzong Chen